- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.07. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 09.06. | Cyclerion Therapeutics, Inc. - S-4/A, Registration of securities, business combinations | 1 | SEC Filings | ||
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 860 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 222 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 22.02. | Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer's Drug | 1 | MedCity News | ||
| 18.02. | Korsana Biosciences Raises $175M in Funding | 1 | FinSMEs | ||
| 17.02. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | Cyclerion receives FDA feedback on depression treatment development | 6 | Investing.com | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 179 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen | |
| 23.09.25 | Cyclerion Therapeutics, Inc.: Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company | 316 | GlobeNewswire (Europe) | - Cyclerion Relaunches, Advancing a Phase 2-Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement - - Webcast to be held September 24, 2025 at 10:30 a.m.... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,190 | +1,04 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,102 | +2,04 % | CARDIOL THERAPEUTICS INC ruhig im strategischen Fokus | ||
| CELLECTAR BIOSCIENCES | 2,540 | +1,20 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| CYTODYN | 0,198 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,789 | +3,68 % | CARDIFF ONCOLOGY INC im strukturellen Gleichgewicht | ||
| RECURSION PHARMACEUTICALS | 2,945 | -2,48 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,670 | -0,74 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 19,670 | -1,06 % | Will Recent Setbacks Impact Growth Prospects of DNLI Stock? | ||
| CEL-SCI | 1,000 | 0,00 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 68,32 | -2,76 % | Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet | ||
| BEAM THERAPEUTICS | 27,530 | -3,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,220 | +1,41 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,220 | +7,38 % | XFRA CUS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,240 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen |
CYCLERION THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 3,650 Euro und damit -0,27 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.